1 Alteration of serum leptin and LEP/LEPR promoter methylation in Prader-Willi

2 syndrome

- 3
- 4 Jelte Wieting a*, Kirsten Jahn a*, Vanessa Buchholz a, Ralf Lichtinghagen b, Stefan Bleich a,

5 Christian K. Eberlein *a*, Maximilian Deest *a**, Helge Frieling *a**

6

7 a Hannover Medical School, Department for Psychiatry, Social Psychiatry and Psychotherapy, Carl-Neuberg-Str. 1, 30626,

8 Hannover, Germany

9 *b* Hannover Medical School, Department for Clinical Chemistry, Carl-Neuberg-Str. 1, 30626, Hannover, Germany

10

11 * JW and KJ should be considered joint first author. MD and HF should be considered joint senior author.

12

Corresponding Author: Dr. med. Jelte Wieting, Hannover Medical School, Department for Psychiatry, Social Psychiatry and Psychotherapy, Carl-Neuberg-Str. 1, 30626, Hannover, Germany; mailto: wieting.jelte@mh-hannover.de, phone +4917615328338

16

17 ABSTRACT

18 Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder based on a loss of paternally expressed 19 but maternally imprinted genes in chromosome region 15q11-13. During child development, PWS usually 20 results in insatiable appetite with subsequent obesity representing the major mortality factor. The 21 neurobiological basis of PWS-typical hyperphagia has remained poorly understood. Many PWS-typical 22 abnormalities are based on hypothalamic dysregulation, the region in which hunger and satiety are hormonally 23 regulated, with the hormone leptin being a main long-term regulator of satiety. Previous studies in PWS have 24 inconsistently shown leptin alterations solely in early childhood, without investigating the leptin system on an 25 epigenetic level. 26 The present study investigates serum leptin levels (S-leptin) and methylation of the leptin (LEP) and leptin

27 receptor gene (LEPR) promoter in 24 individuals with PWS compared to 13 healthy controls matched for sex,

28 age, and body mass index (BMI) and relates the results to the extent of hyperphagia in PWS.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 S-Leptin levels were obtained by Enzyme-linked Immunosorbent Assay. LEP/LEPR-promoter methylation was

30 assessed by DNA-bisulfite-sequencing, hyperphagia by Hyperphagia Questionnaire for Clinical Trials (HQ-CT).

31 PWS and control groups differed significantly in S-leptin levels with higher S-leptin in PWS. Methylation analysis

32 showed significant differences in mean promoter methylation rate both for LEP and LEPR with a lower

33 methylation rate in PWS. LEPR, but not LEP methylation correlated with S-leptin levels. S-leptin and both LEP

34 and LEPR methylation did not correlate with HQ-CT scores in PWS.

The present study is the first to show significantly elevated S-leptin levels in an adult PWS cohort combined with an altered, downregulated LEP and LEPR promoter methylation status compared to BMI-matched controls. Analogous to previous studies, no link to the behavioral dimension could be drawn. Overall, the results suggest an increased leptin dysregulation in PWS, whereby the findings partly mirror leptin resistance seen in non-syndromic obesity.

40

41 INTRODUCTION

Prader-Willi syndrome (PWS) is a rare neuronal developmental disorders with an estimated prevalence of 1:15000 (1). The syndrome is genetically determined by a loss of normally paternally expressed but maternally imprinted genes on chromosome 15q11-13. Essentially, three different genetic subtypes can lead to PWS. Most common, in about 70% of cases, is a large deletion of the paternal allele of chr15q11-13 (delPWS). In about 25-30% of cases a maternal uniparental disomy of chromosome 15 (UPD) and in rare cases, a defect of the imprinting center (IC) occurs (2).

48 Newborns initially present with a failure to thrive and muscular hypotension. During infancy, PWS individuals 49 rapidly develop an insatiable appetite leading to massive weight gain unless food intake is regulated. 50 Individuals with PWS show a deficiency of growth hormones and hypogonadism, accompanied by a 51 dysregulation of body temperature and altered pain tolerance, which can essentially be explained by 52 hypothalamic dysfunction (3). In addition, in almost all cases there is a mild to moderate intellectual 53 impairment as well as an overall delay in language and motor development. But also, individuals with PWS 54 exhibit a certain behavioral phenotype characterized by temper outbursts, repetitive and ritualistic behaviors, 55 and skin-picking(4). Despite improved diagnostics and therapy, life expectancy is still assumed to be reduced in 56 people with PWS. Obesity and its sequelae such as cardiovascular diseases, diabetes, as well as sleep apnea and 57 other respiratory complications are the major driving factor for the increased mortality rate in people with PWS

58 (5). Therefore, basic research into the causes of hyperphagia and obesity in PWS is of particular importance for

59 improved diagnosis and treatment.

60

61 In human, satiety is induced essentially via stimulation of melanocortin-4 receptors (MCR-4) by the 62 proopiomelanocortin (POMC) derivative alpha- melanocyte stimulating hormone (alpha-MSH) in the 63 paraventricular nucleus of the hypothalamus. Besides stimulation of POMC, leptin inhibits AgRP- and 64 neuropeptide Y (NPY)-producing neurons in the arcuate nucleus of hypothalamus, hormones, which have an 65 appetite-increasing effect via MCR-4 inhibition. Leptin has an appetite suppressing, energy expenditure 66 increasing and consequently body weight reducing effect (6). Animal studies suggest that leptin receptors are 67 also found in the ventral tegmental and other midbrain areas, in which the regulation of the endogenous 68 reward system is mediated (7).

69 In humans, the hormone leptin is encoded on the LEP gene located on chromosome 7q31.3 and composed of 70 three exons and two introns. It is largely expressed in adipocytes, but also to a lesser extent centrally in the 71 hypothalamus and pituitary gland, as well as other tissues (8). The physiological regulatory mechanisms behind 72 leptin expression are complex. In healthy individuals, leptin blood levels correlate with body fat stores (9). In 73 women, circulating leptin is significantly elevated compared to men. With increasing age leptin levels decrease 74 (10). Fasting causes a decrease in leptin levels in humans, whereas levels re-increase after days of refeeding 75 (11). It is important to note that leptin levels do not increase in response to individual meals (12). Leptin can be 76 considered as a long-term indicator of the body's energy reserves.

Leptin exerts its effect via leptin receptors. The LEPR gene is located on chromosome 1 (1p31) and consists of 18 exons and 17 introns. One of the splice variants of the LEPR gene, the longest isoform LEPRb is most widely expressed in the human brain, particularly in the hypothalamus and cerebellum, although leptin receptors are also expressed in other tissues such as the vasculature and stomach. Only the long isoform LepRb contains the intracellular motif required for leptin-mediated POMC-activation in the hypothalamus, making this isoform the main mediator of the above-mentioned leptin-specific effects (13).

Due to its size, leptin is unable to cross the blood-brain barrier (BBB) by diffusion. The neurobiological mechanisms of transporting leptin across the BBB are mainly unclear. In obese individuals, elevated leptin levels continue to be seen in both blood and adipocytes, but no significant leptin effect can be discerned. Accordingly, leptin resistance in obesity is assumed. Most of the evidence on the cellular and molecular

87 mechanisms of leptin resistance has been obtained in experimental rodent models. Obese mice showed 88 resistance to peripherally administered leptin but responded to intracerebroventricular infusions of leptin. The 89 efficiency of central leptin uptake measured as CSF/plasma leptin ratio was 4.3-fold higher in lean than in 90 obese subjects indicating a dysregulated leptin transport across the BBB to be associated with leptin resistance. 91

92 The causes for obesity in PWS are currently understood in rudimentary terms at best. Misbalances in the 93 abovementioned hypothalamic satiety center and the various hormones influencing it have been suspected 94 with the hyperphagia typical of PWS. Regarding leptin, significant differences in blood levels compared with 95 obese controls have so far only been demonstrated for young children with PWS. Previous studies showed 96 significantly higher leptin levels in infants <6 years of age compared to weight-matched controls in collectives 97 sized 42 PWS to nine control (14) and 33 PWS to 28 control subjects (15), whereas this finding was absent in 98 children >6 years of age in a study sized 35 PWS (n=21 <6y, n=14 >6y) and 31 age and BMI-matched controls 99 (16). 22 adult patients with PWS showed elevated blood leptin levels compared to 54 healthy controls (17), but 100 in adult PWS there were no significant differences compared to weight-adapted control subjects in cohorts of 101 20 PWS to 14 control (18) and 28 PWS to 29 obese control subjects (19). An older study by Butler et al. also 102 showed no relevant differences between PWS and BMI-matched controls (PWS n=19 obese and n=14 non-103 obese, controls n=28 obese and n=16 non-obese), with the exception that non-overweight male PWS subjects 104 had five times higher plasma leptin levels than controls (20). On a genetic level, Lindgren et al. examined leptin 105 mRNA levels in subcutaneous adipose tissue in comparison of healthy controls and PWS children on the one 106 hand and non-syndromic obesity on the other. Leptin mRNA levels were found to be significantly increased in 107 both PWS and non-syndromic obese controls compared with healthy subjects, but there was no significant 108 difference between PWS and non-syndromic obese controls. Both leptin serum and leptin mRNA levels 109 correlated with BMI in PWS. However, the results are clearly limited by the small number of cases (n=6 each) 110 (21).

111

Preliminary studies illuminated the influence of epigenetic mechanisms on hormone balance, including leptin, which is investigated in the present work. One important epigenetic mechanism is the methylation of cytosine bases in the DNA strand, which occurs only in the context of cytosine-guanine dinucleotides (CpGs). Methylation of the gene promoter is of particular interest in that it represents an essential regulatory unit for

116 gene expression. Among other mechanisms, increased methylation impedes the binding of transcription factors

117 so that protein biosynthesis is subsequently suppressed (22).

118 In the context of metabolic diseases, research results are available from both animal and human studies 119 regarding altered LEP methylation status and leptin expression. In human studies, an association between 120 decreased LEP-methylation status and obesity has been demonstrated in male children (23). In obese 121 adolescents, a decreased methylation status of the LEP promoter region was detected in peripheral blood (24). 122 Overall, the data predominantly indicate hypomethylation of the LEP promoter region in metabolic disorders. 123 In general, an inverse correlation between LEP promoter methylation and leptin expression is assumed (25). 124 In our previous publication on the subject, we examined 98 obese patients before and after bariatric surgery 125 with respect to LEP promoter methylation and leptin expression. Consistent with previous studies, we saw 126 increased leptin serum levels before bariatric surgery. But in contrast to the majority of studies regarding LEP 127 promoter methylation, we found an increased LEP promoter methylation before surgery compared with 128 postoperative levels (26).

Alterations of the LEPR gene in obesity have been less studied overall. In the aforementioned study on bariatric surgery, there was an increased postoperative LEPR methylation accompanied by an inverse association between LEPR methylation and S-leptin levels. Furthermore, another study on the influence of pre-pregnancy BMI on gestational weight suggested an inverse correlation between LEPR methylation and LepRb expression (27).

134

In the present study, we investigate the leptin system in an adult PWS collective compared to healthy BMImatched controls. For the first time, we assess the regulatory level in terms of LEP and LEPR promoter methylation in PWS. The results will be related to the extent of hyperphagia the PWS subjects undergo, which is assessed by a specific questionnaire.

139

140 methods

141 STUDY CHARACTERISTICS

The study included 24 subjects with PWS (14 male, 10 female) and 13 healthy control subjects (8 male, 5 female) matched for sex, age, and body mass index (BMI). Control subjects with a difference of +/- 5 years and +/- 1 kg/m² BMI compared to the study cohort were considered. The control subjects were recruited via public

tenders analogously and online. The healthy control subjects confirmed during the interview that they had not been diagnosed with any mental illness at the time of the study. The participants of this study are part of a larger register study entitled PSY-PWS which takes place at Hannover Medical School and is described in more detail in former publications (28,29). The study followed the Declaration of Helsinki and was reviewed and approved by the local ethics committee of Hannover Medical School (No: 8129_BO_S_2020). All subjects or their legal representatives gave written informed consent to participation after all study procedures were explained to them.

152

The HQ-CT (Hyperphagia Questionnaire for Clinical Trials) in German language was used to assess the level of hyperphagia-related behavior in PWS. The HQ-CT is specifically designed and validated for PWS. It is a 9-item caregiver-report test instrument considered to be the current gold standard for hyperphagia assessment in PWS. The HQ-CT total score results from the sum of the 9 item-level responses ranging from 0 to 4 with a maximum score of 36 (30). Cut-off values above which clinically significant symptoms can be assumed have not yet been established.

159

160 MOLECULAR ANALYSIS

161 DNA was extracted from blood samples using chemagicStar DNA-Blood1k kit (PerkinElmer Chemagen 162 Technology, Baesweiler, Germany). The genomic DNA was subsequently bisulfite converted using the EpiTect® 163 96 Bisulfite Kit (Qiagen, Hilden, Germany) to detect the methylation status of the cytosine bases. Our target 164 sequences within the LEP and LEPR promoter region were amplified from the previously purified bisulfite-165 converted DNA by polymerase chain reaction. Primers were designed to cover a LEP fragment of 823 bp (Hg 38, 166 Chr. 7: 128.240.657 to 128.241.478), including exon 1 (Hg 38, Chr.7: 128.241.277 to 128.241.306), with 65 CpG-167 sites covered, and a LEPR fragment of 461 bp length (Hg 38, Chr. 1: 65.420.416 to 65.420.876), including exon 1 168 (Hg 38, Chr. 1: 65.420.651 to 65.420.741). The number of covered CpG-sites was 46. 169 Sequencing was performed using the Big-Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,

170 Foster City, CA, USA). Individual PCR protocols and primer sequences can be found in Supplementary Material

171 **S1**.

172

- 173 To determine the methylation status of the different CpG loci from the data obtained by DNA sequencing,
- 174 Epigenetic Sequencing Methylation Analysis Software (ESME) was used (31). Methylation for each CpG site was
- 175 calculated per each subject by building the ratio between normalized peak values of cytosine and thymine.
- 176
- 177 S-leptin levels were determined by enzyme-linked immunosorbent assay (ELISA) from Serum blood samples
- 178 using Quantikine® Human Leptin Immunoassay (R&D Systems, Minneapolis, MN, USA).
- 179
- 180 STATISTICS
- 181 Sequence Scanner v2.0 software (ABI Life Technologies, Grand Island, NY, USA) was used for sequence quality
- 182 control. Only sequences showing a QV (quality value) > 20 were included for further analysis.

183 For statistical analysis, we used SPSS (IBM, Armonk, NY, USA). For graphical data processing, Graph Pad Prism

- 184 (GraphPad, LaJolla, CA, USA) was used.
- 185 Data were further checked for missing values and variance. Single CpGs with more than 5% missing values and
- 186 inter-individual variability below 5% were removed from the analysis. In addition, subjects with more than 5%
- 187 missing values in methylation rate were excluded (see Supplementary Material S2).
- 188

Mann-Whitney test was used to compare differences in S-leptin levels and BMI between PWS and control subjects. We calculated mixed linear models to detect fixed effects of the variable group (PWS or control), CpGposition, sex and BMI on methylation rate. BMI and age were set as parameters of covariance. Bonferroni correction was applied to correct p-values for multiple testing. Differences in methylation rates at individual CpG sites were assessed within the mixed linear model with data splitted for CpG site. Fixed effects of factor group were calculated for the individual CpG sites. p values of < 0.05 were considered significant.

195

To assess the correlation between HQ-CT and the LEP/LEPR methylation in total and for individual CpG sites Pearson's correlation coefficient was calculated. In addition, two groups were derived from the HQ-CT scores, with one group below and another group equal to or above the surveyed median HQ score of 8 in the PWS group for comparing LEP/LEPR methylation in pronounced hyperphagia with less pronounced hyperphagia. To this end, we examined effects of the factor "clinical severity of hyperphagia" on methylation rate according to the MLM detailed above and made group-wise comparisons.

203	RESULTS
204	PATIENT CHARACTERISTICS
205	The study included 24 subjects with Prader-Willi syndrome (male n=14, 58.3%; female n=10, 41.7%) and 13
206	healthy control subjects (male n=8, 61.5%; female n=5, 38.5%). In PWS subjects, the mean age was 27 years
207	(minimum 12y, maximum 55y), whereas in controls, the mean age was 32 years (minimum 18y, maximum 47y).
208	As matched for this, BMI values differed only slightly between groups showing no significant difference
209	according to Mann Whitney test, U = 166, Z= 0.318, p = 0.766. Mean BMI was 27.2 kg/m ² in PWS (Minimum
210	19.1 kg/m², Maximum 39.1 kg/m²) and 26.6 kg/m² in healthy controls (Minimum 19.4 kg/m², Maximum 40.0
211	kg/m ²). Genetic subtype was determined in all subjects with PWS. DelPWS (n=11) and UPD (n=7) were shown
212	most frequently (UPD/IC n=4 and IC n=2). Mean HQ-RT score in the PWS group was 10.39 (median 8, minimum
213	1, maximum 33).
214	Table 1 presents the patient characteristics in detail.
215	
216	S-LEPTIN
217	Mean S-Leptin in PWS subjects was 32.747 ng/ml (Minimum 3.261 ng/ml, Maximum 79.822 ng/ml) and 11.928

ng/ml in control group (Minimum 0.116 ng/ml, Maximum 43.797 ng/ml). Divided by sex, female subjects had
higher serum leptin levels than males in both the PWS and control groups. Male PWS had a mean leptin level of
26,608 ng/ml (min 3,261, max 79,822), female of 41,316 ng/ml (min 14,755, max 68,826). Controls also showed
a difference between males with an average of 5.324 ng/ml (Min 0.116, Max 16.213) to 22.493 ng/ml (Min
7.068, Max 43.797) in female controls.

According to Mann Whitney test for comparison of PWS and control groups in terms of S-leptin levels there was a significant difference between the groups, U = 245.00, Z= 2.831, p = 0.004 (see **Table 1** and **Figure 1**).

225 Serum leptin levels correlate highly positively with BMI in both PWS subjects (linear R2 = 0.502) and healthy

control subjects (linear R2 = 0.623). S-Leptin values do not correlate with the HQ results in the PWS subjects

227 (linear R2 = 0.016).

228

202

229 LEP METHYLATION

230 For LEP significant fixed effects on methylation rate of individual CpG position ($F_{(48,1660)}$ = 85,312; p < 0.001) and 231 group (F (1.1660) = 22,706, p < 0.001) were detected. MLM revealed no significant CpG x group interaction for LEP 232 gene (F $_{[48,1660]}$ = 1,247; p = 0,121). We found independent effects of age (F $_{(1,1660)}$ = 34,185; p < 0,001), but not 233 of sex ($F_{(1, 1660)}$ = 2,657, p = 0,103) nor BMI ($F_{(1, 1660)}$ = 1,52, p = 0,218). Significance of group differences was not 234 affected when age and gender were applied as additional factors. 235 Overall LEP mean methylation rate was shown to be lower in PWS (29.9%) compared to healthy controls 236 (32,5%) (see Figure 2). Analysis of fixed effects of factor group on single CpG sites methylation revealed 237 significant effects for eleven individual CpG positions (m169, m199, m203, m329, m331, m338, m340, m349, 238 m371, m373 and m378). All CpG sites named above showed a significantly lower mean methylation rate in the 239 PWS group compared to controls. The CpG positions m329 and m331, m338 and m 340, and m349 to m373 240 sequentially follow each other in the base sequence. Figure 3 shows a graphical representation of these results. 241 No significant differences in mean methylation rate were found between the sexes with males showing an 242 insignificantly higher methylation rate (31,6%) compared to females (30,8%). For detailed statistical results see 243 Supplementary Material S3. 244 Correlation analysis revealed no significant correlation between overall LEP promoter methylation rate and S-245 Leptin levels. Also, there was no correlation between overall LEP methylation and HQ scores. 246 According to Pearson's r, there was a negative correlation between mean methylation at CpG sites m349 (r = -247 0.473, p = 0.023) and m371 (r = - 0,462, p = 0,026) and HQ scores in subjects with PWS. No significant 248 correlation was found for any other LEP CpG site shown to differ significantly between the groups in LEP 249 methylation rate. The MLM showed no significant effect of the factor "clinical severity of hyperphagia" on the

250 methylation rate ($F_{(1,1076)} = 1.571$; p = 0.210).

251

252 LEPR METHYLATION

MLM revealed significant fixed effects of factors group ($F_{(1,813)} = 11,021$; p = 0.001) as well as CpG-position ($F_{(23,813)} = 8,984$; p < 0.001) on the LEPR methylation rate. Overall LEPR mean methylation rate was lower in PWS with 3.0% compared to 4.4% in controls. In contrast to LEP analysis, we showed a significant group x CpG site interaction for LEPR gene ($F_{(23,813)} = 2,414$; p < 0.001). No significant fixed effects were seen for factor sex on methylation rate (p = 0.279), nor for age (p = 0.977) or BMI (p = 0.382). Significance of group differences was not affected when age and gender were applied as additional factors.

259 Within the mixed linear model analysis split for single CpG sites, significant effects of factor group at eight 260 individual CpG positions were seen (m211, m196, m86, m4, p31, p76, p88 and p129). No contiguous CpG 261 positions could be identified. Figure 4 shows a graphical representation of these results. For detailed statistical 262 results see Supplementary Material S4. 263 Correlation analyses showed a highly significant inverse correlation between overall LEPR methylation rate and 264 S-Leptin levels with Pearsons r = -0.120, p < 0.001. No correlation was found between overall LEPR methylation 265 rate and HQ scores. There were no correlations of individual CpG sites methylation rate with HQ scores. 266 The MLM showed no significant effect of the factor "clinical severity of hyperphagia" on the methylation rate (F 267 $_{(1.503)} = 0.018; p = 0.893).$ 268 269 DISCUSSION

The present study investigates serum leptin levels and methylation of the LEP and LEPR promoter in adult PWS compared to healthy BMI-matched controls. Our study reveals that PWS subjects have significantly higher Sleptin levels than controls while showing significantly downregulated LEP and LEPR promoter methylation. LEPR, but not LEP methylation correlated with S-leptin levels, while overall there was no correlation with the behavioral dimension in terms of the HQ-scores.

275

276 To our knowledge, the study is the first to demonstrate a significant difference in serum leptin levels between 277 obese adults with PWS and weight-matched controls, a finding previously shown only for infants <6 years of 278 age that appeared to resolve with increasing age. In line with previous studies a correlation of leptin level with 279 BMI was still observed in both PWS and control group in the present study, but as they were matched for BMI 280 both the PWS and control group were only slightly overweight at 27.2 respective 26.6 kg/m². The mean BMI of 281 our study seems to be considerably lower compared to other studies on the topic, for example, 37.2 kg/m² in 282 Butler et al. or 41.2 kg/m² in Pagano et al. (19,20). Altogether, a BMI-independent effect of the factor PWS on 283 S-leptin levels can be assumed. The comparatively high number of male subjects in our study might have a 284 confounding effect, especially since sex-dependent differences in leptin regulation are known. An indication 285 could be the study by Butler et al., which showed comparatively higher leptin blood levels only in male PWS 286 subjects, who, unlike in our study, were non-obese (20). But this idea again conflicts with previous findings that 287 women generally have higher leptin levels than men. In contrast, Kennedy et al. also showed no differences in

leptin levels between PWS and overweight controls, although females significantly predominated in the PWS
 cohort (18). Our results displayed no significant differences between the sexes in terms of blood leptin levels.

290

291 Furthermore, the present study is the first to investigate the epigenetic regulation of the satiety hormone 292 leptin in people with PWS. In terms of obesity in general the majority of previous human studies have 293 demonstrated an association between decreased LEP methylation levels and elevated leptin serum levels in 294 obese subjects, hence an inverse correlation between LEP promoter methylation and leptin expression was 295 assumed. Our results appear partly conclusive on this point from a neurobiological perspective, although it 296 should be mentioned that no significant correlation was shown between LEP promoter methylation and S-297 leptin levels. Also, Lindgren et al. found no difference in leptin mRNA levels between PWS and obese controls, 298 although increased leptin protein biosynthesis might be expected with decreased LEP promoter methylation as 299 found in the present cohort (21). Also, data from our laboratory regarding LEP promoter methylation after 300 bariatric surgery recently indicated decreased LEP promoter methylation with concomitant decreased serum 301 leptin after surgically induced weight loss, contrary to the majority of observations made before (26). Overall, 302 however, intervention-induced weight loss with the accompanying hormonal disruptions appears to bear little 303 resemblance to the given conditions in PWS. In contrast, analogous to the study by Wilhelm et al, we also see 304 an inverse correlation between LEPR methylation and S-leptin levels in the present cohort. Taken together, the 305 findings of hypomethylated LEP/LEPR promoter and elevated S-leptin made in our PWS cohort mirror those 306 previously made in obesity in general.

With central leptin resistance known to occur in obesity and suspected in PWS, a previous study suggested that above a count of 25-30ng/ml S-leptin central leptin resistance can be assumed (32), a limit which is exceeded by our PWS cohort. Given the abovementioned similarities of our findings in PWS to obesity in general, could PWS even serve as a model disease for leptin resistance?

311

The following hypothesis appears to emerge from the evidence to date. Among the chromosomal region affected in PWS is the melanoma antigen gene family member L2 (MAGEL2) gene. It is known that leptinmediated activation of anorexigenic POMC neurons in the arcuate nucleus of the hypothalamus is mediated via leptin receptors LepRb. Leptin-induced POMC-activation was absent in a Magel2 knockout mouse model, suggesting that MAGEL2 is required for the leptin-mediated responses that is critical for POMC neuron-

317 mediated suppression of food intake (33). To that end, it can be hypothesized that loss of Magel2 disrupts the 318 normal balance of LepR cell surface expression, because MAGEL2 and Necdin, another gene encoded in the 319 PWS region, regulate the linkage of leptin receptors to an ubiquitination complex relevant for surface 320 expression, internalization, and degradation processes. In contrast, while MAGEL2 is normally associated with 321 cell surface abundance of LepR and its reduced degradation, the hypothalamus of Magel2-null mice showed 322 less LepR and altered levels of proteins of the ubiquitin pathway that regulate LepR processing (34). 323 Hypothalamic LepRbs are generally suspected to be involved in the development of leptin resistance. 324 Downregulation of LepRb mRNA and proteins and impaired transport of LepRb to the plasma membrane in 325 neuronal subpopulations of hypothalamic nuclei that control energy homeostasis have emerged as possible 326 molecular mechanisms of leptin resistance before (35). Limited by the fact that we only investigated in 327 peripheral blood DNA-methylation, our observation of significantly elevated serum leptin levels with decreased 328 LEP and LEPR promoter methylation could represent a counter regulatory mechanism in response to leptin 329 resistance in PWS genetically determined by MAGEL2 and Necdin derived downregulated LepRb expression in 330 the hypothalamus satiety center. We hypothesize that central leptin resistance is counteracted by upregulated 331 leptin hormone and leptin receptor expression in PWS mediated at the epigenetic level via decreased promoter 332 methylation of LEP and LEPR, as we have seen analogously in previous studies on human obesity showing an 333 inverse correlation between LEPR methylation and LepRb expression, for example (27). We see corroboration 334 of our theory by our observation that LEPR, but not LEP promoter methylation, correlated significantly with S-335 leptin levels in the subjects, suggesting a functional regulatory link for LEPR. However, it remains to be 336 mentioned that Wijesuriya et al. also noted that Magel2 mutation rodent models showed an overall less 337 pronounced hyperphagia phenotype than other models, for example compared to Snord116 gene deficiency.

338

Likewise, our study failed to provide a conclusive link between laboratory findings and the behavioral dimension. Overall, no correlation of serum leptin levels with HQ scores was demonstrated in the PWS subjects. Also, no correlation was found between overall methylation rate of LEP and LEPR with HQ-scores in PWS, however solely for LEP CpG sites m349 and m371. From a neurobiological perspective, our finding that the methylation rates of the abovementioned CpG sites correlate negatively with the outcome of the hyperphagia questionnaire appears inconclusive. As stated above, it should be assumed that increased leptin expression via decreased LEP methylation should be accompanied by an increased feeling of satiety and,

accordingly, by decreased food-seeking behavior, which would correspond to a lower score on the HQ. In this respect, the correlations found seem most likely to be incidental. To this end, our findings appear to be in line with previous human studies on this topic like Goldstone et al. being unable to establish a connection between hormonal abnormalities in PWS and the behavioral dimension in the sense of an altered eating behavior (14). In synopsis of our and previous findings, no connection between leptin regulation and behavioral abnormalities in PWS can be assumed.

353 LIMITATIONS

354 Overall, the cohort size of our study is small, but in line with that of previous studies on the topic.

355 Especially limiting appears the use of peripheral blood material, although the regulation of satiety is essentially

356 due to central processes. Therefore, only indirect conclusions can be drawn regarding the central processes

behind leptin resistance in PWS. Unfortunately, we did not have central material such as CSF available for our

358 study, as such sampling is hardly justifiable from an ethical point of view.

359 Furthermore, the HQ currently is described to be the gold standard for assessing food-seeking behavior in PWS.

However, the overall data on the validity of the questionnaire appears limited. In general, it offers only an indirect assessment, since it is completed by relatives or caregivers, which could be subject to perceptual bias compared to the PWS individuals themselves. Also, the HQ was not performed in the control subjects, so

comparability is not given.

Another crucial limitation of the study seems to be the use of BMI as determinant of obesity in the subjects. BMI values of the control group could likely be confounded by a comparatively increased muscle mass. Body fat percentage could be the much more accurate determinant for comparison at this point, especially since leptin is primarily produced in adipocytes. However, the comparability with previous studies still appears to be given insofar as these also mostly used body weight or BMI as assessment standard.

Furthermore, our study lacks a healthy, normal-weight control group for comparisons regarding leptin
 resistance in obese and non-obese subjects.

371

372 CONCLUSION

The observed differences in leptin expression again pointed towards a dysregulation of the hormonal network
 regulating hunger and satiety in people with PWS without being able to provide a detectable connection of

- 375 leptin dysregulation and food-seeking behavior typical in PWS. But overall, our research findings strengthen the
- 376 hypothesis that PWS could be considered as a model disease for leptin resistance and thus be of great interest
- for obesity research in general.

378

379 CONFLICTS OF INTEREST

- 380 All authors declare to have no conflicts of interest.
- 381

382 AUTHOR CONTRIBUTION

383 Jelte Wieting contributed in acquisition of samples, drafted the manuscript and contributed to analysis and 384 interpretation of data. Kirsten Jahn carried out the experiments and contributed to analysis and interpretation 385 of data. Vanessa Buchholz and Ralf Lichtinghagen carried out the experiments. Christian K. Eberlein contributed 386 to acquisition of samples and contributed to interpretation of data and revised the manuscript critically for 387 important intellectual content. Stefan Bleich contributed to interpretation of data and revised the manuscript 388 critically for important intellectual content. Maximilian Deest contributed to acquisition of samples, analysis, 389 and interpretation of the data and was substantially involved in drafting the manuscript. Helge Frieling 390 contributed to conception and design of the study, interpretation of data, and revised the manuscript critically 391 for important intellectual content.

392

393 REFERENCES

- Lionti T, Reid SM, White SM, Rowell MM. A population-based profile of 160 Australians with Prader Willi syndrome: Trends in diagnosis, birth prevalence and birth characteristics. Am J Med Genet Part A.
 2015;
- Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: A review of clinical, genetic, and
 endocrine findings. J Endocrinol Invest. 2015;
- 399 3. Muscogiuri G, Formoso G, Pugliese G, Ruggeri RM, Scarano E, Colao A. Prader- Willi syndrome: An
 400 uptodate on endocrine and metabolic complications. Reviews in Endocrine and Metabolic Disorders.
 401 2019.
- 402 4. Dykens E, Shah B. Psychiatric disorders in Prader-Willi syndrome: Epidemiology and management. CNS
 403 Drugs. 2003.

- 404 5. Proffitt J, Osann K, McManus B, Kimonis VE, Heinemann J, Butler MG, et al. Contributing factors of
- 405 mortality in Prader-Willi syndrome. Am J Med Genet Part A [Internet]. 2019 Feb 1 [cited 2021 Aug
- 406 20];179(2):196–205. Available from: https://pubmed.ncbi.nlm.nih.gov/30569567/
- 407 6. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative Review: The Role of Leptin in Human
 408 Physiology: Emerging Clinical Applications. Ann Intern Med [Internet]. 2010 Jan 19 [cited 2021 Aug
 409 21];152(2):93. Available from: /pmc/articles/PMC2829242/
- 410 7. Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM, et al. Leptin targets in the mouse
- 411 brain. J Comp Neurol [Internet]. 2009 Jun 10 [cited 2021 Aug 24];514(5):518–32. Available from:

412 https://pubmed.ncbi.nlm.nih.gov/19350671/

- Morash B, Li A, Murphy PR, Wilkinson M, Ur E. Leptin gene expression in the brain and pituitary gland.
 Endocrinology [Internet]. 1999 [cited 2021 Aug 24];140(12):5995–8. Available from:
 https://pubmed.ncbi.nlm.nih.gov/10579368/
- 416 9. Considine R V., Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum 417 Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. N Engl J Med [Internet].
- 418
 1996
 Feb
 [cited
 2021
 Aug
 24];334(5):292–5.
 Available
 from:

 419
 https://pubmed.ncbi.nlm.nih.gov/8532024/
 https://pubmed.ncbi.nlm.nih
- 420 10. Ostlund RE, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat,
 421 gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab [Internet]. 1996 Nov [cited 2021
 422 Aug 24];81(11):3909–13. Available from: https://pubmed.ncbi.nlm.nih.gov/8923837/
- Kolaczynski JW, Considine R V., Ohannesian J, Marco C, Opentanova I, Nyce MR, et al. Responses of
 leptin to short-term fasting and refeeding in humans: A link with ketogenesis but not ketones
 themselves. Diabetes [Internet]. 1996 [cited 2021 Aug 24];45(11):1511–5. Available from:
 https://pubmed.ncbi.nlm.nih.gov/8866554/
- 427 12. Korbonits M, Trainer PJ, Little JA, Edwards R, Kopelman PG, Besser GM, et al. Leptin levels do not 428 change acutely with food administration in normal or obese subjects, but are negatively correlated with 429 pituitary-adrenal activity. Clin Endocrinol (Oxf) [Internet]. 1997 [cited 2021 Aug 24];46(6):751–7.
- 430 Available from: https://pubmed.ncbi.nlm.nih.gov/9274707/
- 431 13. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and
 432 body weight in humans: A review [Internet]. Vol. 8, Obesity Reviews. Obes Rev; 2007 [cited 2021 Aug

433 24]. p. 21–34. Available from: https://pubmed.ncbi.nlm.nih.gov/17212793/

434 14. Goldstone AP, Holland AJ, Butler J V., Whittington JE. Appetite hormones and the transition to
435 hyperphagia in children with Prader-Willi syndrome. Int J Obes [Internet]. 2012 Dec [cited 2021 Aug
436 21];36(12):1564-70. Available from: https://pubmed.ncbi.nlm.nih.gov/22270375/

- Haqq AM, Grambow SC, Muehlbauer M, Newgard CB, Svetkey LP, Carrel AL, et al. Ghrelin
 concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development. Clin
 Endocrinol (Oxf) [Internet]. 2008 Dec [cited 2021 Aug 21];69(6):911. Available from:
 /pmc/articles/PMC2614621/
- Orsso CE, Butler AA, Muehlbauer MJ, Cui HN, Rubin DA, Pakseresht M, et al. Obestatin and adropin in
 Prader-Willi syndrome and nonsyndromic obesity: Associations with weight, BMI-z, and HOMA-IR.
 Pediatr Obes [Internet]. 2019 May 1 [cited 2021 Aug 21];14(5):e12493. Available from:
 /pmc/articles/PMC7456601/
- Hirsch HJ, Gross I, Pollak Y, Eldar-Geva T, Gross-Tsur V. Irisin and the Metabolic Phenotype of Adults
 with Prader-Willi Syndrome. PLoS One [Internet]. 2015 Sep 3 [cited 2021 Aug 21];10(9). Available from:
 /pmc/articles/PMC4559418/
- Kennedy L, Bittel D, Kibiryeva N, Kalra S, Torto R, Butler M. Circulating adiponectin levels, body
 composition and obesity-related variables in Prader–Willi syndrome: comparison with obese subjects.
 Int J Obes (Lond) [Internet]. 2006 Feb [cited 2021 Aug 21];30(2):382. Available from:
 /pmc/articles/PMC6704478/
- 452 19. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, et al. Increased serum resistin in adults 453 with Prader-Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 454 [Internet]. 2005 cited 2021 Jul Aug 21];90(7):4335-40. Available from: 455 https://pubmed.ncbi.nlm.nih.gov/15870134/
- 456 20. Butler MG, Moore J, Morawiecki A, Nicolson M. Comparison of Leptin Protein Levels in Prader-Willi
 457 Syndrome and Control Individuals. Am J Med Genet [Internet]. 1998 Jan 6 [cited 2021 Aug 20];75(1):7.
 458 Available from: /pmc/articles/PMC6775636/
- Lindgren AC, Marcus C, Skwirut C, Elimam A, Hagenas L, Schalling M, et al. Increased leptin messenger
 RNA and serum leptin levels in children with Prader-Willi syndrome and nonsyndromal obesity. Pediatr
 Res [Internet]. 1997 [cited 2021 Aug 21];42(5):593–6. Available from:

- 462 https://pubmed.ncbi.nlm.nih.gov/9357929/
- 463 22. Bird A. DNA methylation patterns and epigenetic memory [Internet]. Vol. 16, Genes and Development.
- 464
 Genes
 Dev;
 2002
 [cited
 2021
 Aug
 25].
 p.
 6–21.
 Available
 from:

 465
 https://pubmed.ncbi.nlm.nih.gov/11782440/

 <t
- 46623.Dunstan J, Bressler JP, Moran TH, Pollak JS, Hirsch AG, Bailey-Davis L, et al. Associations of LEP, CRH,467ICAM-1, and LINE-1 methylation, measured in saliva, with waist circumference, body mass index, and468percent body fat in mid-childhood. Clin Epigenetics [Internet]. 2017 Mar 29 [cited 2021 Aug 24];9(1).
- 469 Available from: https://pubmed.ncbi.nlm.nih.gov/28360946/
- García-Cardona MC, Huang F, García-Vivas JM, López-Camarillo C, Del Río Navarro BE, Navarro Olivos E,
 et al. DNA methylation of leptin and adiponectin promoters in children is reduced by the combined
 presence of obesity and insulin resistance. Int J Obes [Internet]. 2014 Nov 13 [cited 2021 Aug
 24];38(11):1457–65. Available from: https://pubmed.ncbi.nlm.nih.gov/24549138/
- Melzner I, Scott V, Dorsch K, Fischer P, Wabitsch M, Brüderlein S, et al. Leptin gene expression in
 human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its
 proximal promoter. J Biol Chem [Internet]. 2002 Nov 22 [cited 2021 Aug 24];277(47):45420–7. Available
 from: https://pubmed.ncbi.nlm.nih.gov/12213831/
- Wilhelm J, Birkenstock A, Buchholz V, Müller A, Aly SA, Gruner-Labitzke K, et al. Promoter Methylation
 of LEP and LEPR before and after Bariatric Surgery: A Cross-Sectional Study. Obes Facts [Internet]. 2021
- 480 Mar 1 [cited 2021 Sep 20];14(1):93–9. Available from: https://pubmed.ncbi.nlm.nih.gov/33530087/
- 481 27. Chavira-Suárez E, Ramírez-Mendieta AJ, Martínez-Gutiérrez S, Zárate-Segura P, Beltrán-Montoya J, 482 Espinosa-Maldonado NC, et al. Influence of pre-pregnancy body mass index (p-BMI) and gestational 483 weight gain (GWG) on DNA methylation and protein expression of obesogenic genes in umbilical vein. 484 PLoS One [Internet]. 2019 Dec 1 [cited 2021 Nov 24];14(12). Available from: 485 https://pubmed.ncbi.nlm.nih.gov/31794592/
- 486 28. Deest M, Jakob MM, Seifert J, Bleich S, Frieling H, Eberlein C. Sertraline as a treatment option for
 487 temper outbursts in Prader–Willi syndrome. Am J Med Genet Part A. 2020;
- 48829.Deest M, Buchholz V, Jahn K, Eberlein C, Bleich S, Frieling H. Hypomethylation of monoamine oxidase A489promoter/exon 1 region is associated with temper outbursts in Prader-Willi syndrome. J Psychiatr Res.
- 490 2021 Nov 9;

491	30.	Fehnel SE, Brown TM, Nelson L, Chen A, Kim DD, Roof E, et al. Development Of The Hyperphagia								
492		Questionnaire For Use In Prader-Willi Syndrome Clinical Trials. Value Heal [Internet]. 2015 May 1 [cited								
493		2021 Aug 9];18(3):A25. Available from:								
494		http://www.valueinhealthjournal.com/article/S1098301515002119/fulltext								
495	31.	Lewin J, Schmitt AO, Adorján P, Hildmann T, Piepenbrock C. Quantitative DNA methylation analysis								
496		based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics [Internet].								
497		2004 Nov 22 [cited 2021 Aug 9];20(17):3005-12. Available from:								
498		https://pubmed.ncbi.nlm.nih.gov/15247106/								
499	32.	Holtkamp K, Hebebrand J, Mika C, Heer M, Heussen N, Herpertz-Dahlmann B. High serum leptin levels								
500		subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa.								
501		Psychoneuroendocrinology [Internet]. 2004 Jul [cited 2021 Nov 22];29(6):791–7. Available from:								
502		https://pubmed.ncbi.nlm.nih.gov/15110928/								
503	33.	Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, et al. Acute effects of leptin require PI3K								
504		signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest [Internet]. 2008 May 1								
505		[cited 2021 Nov 23];118(5):1796–805. Available from: https://pubmed.ncbi.nlm.nih.gov/18382766/								
506	34.	Wijesuriya TM, De Ceuninck L, Masschaele D, Sanderson MR, Carias KV, Tavernier J, et al. The Prader-								
507		Willi syndrome proteins MAGEL2 and necdin regulate leptin receptor cell surface abundance through								
508		ubiquitination pathways. Hum Mol Genet [Internet]. 2017 Nov 1 [cited 2021 Aug 25];26(21):4215-30.								
509		Available from: https://pubmed.ncbi.nlm.nih.gov/28973533/								
510	35.	Genchi VA, D'oria R, Palma G, Caccioppoli C, Cignarelli A, Natalicchio A, et al. Impaired Leptin Signalling								
511		in Obesity: Is Leptin a New Thermolipokine? Int J Mol Sci [Internet]. 2021 Jun 2 [cited 2021 Nov								
512		22];22(12). Available from: /pmc/articles/PMC8235268/								

513





Figure 1 Chart showing significant higher mean S-Leptin (with SD) in PWS compared to BMI-matched controls



Figure 2 Chart showing significant lower mean LEP and LEPR promoter methylation (with SD) in PWS compared to BMI-matched controls



Figure 3 Chart revealing significant lower mean methylation of LEP-promoter (with SD) in eleven of partially contiguous CpG regions in PWS compared to controls (only shown CpG sites with a significant difference)

LEP methylation per CpG site



Figure 4 Chart revealing significant difference in mean methylation of LEPR-promoter (with SD) in eight CpG regions in comparison of PWS and controls (only shown CpG sites with a significant difference)

Tables

	PWS	Control					
n=	24	13					
Sex	14 male (58.3%), 10 female (41.7%)	8 male (61.5%), 5 female (38.5%)					
Subtype	11 DelPWS	7 UPD	2 IC	4 UPD/IC			
					Mann-Whitney-U-test		J-test
	Mean Age (in y)	Min	Max	SD	U	Z	р
PWS	27	12	55	12.044	107	1.561	0.124
control	32	18	47	8.140			
	Mean BMI (kg/m ²)						
PWS	27.20	19.100	39.111	5.793	166	0.318	0.766
control	26.60	19.370	40.009	5.467			
	Mean S-leptin (ng/m∣)						
PWS	32.747	3.261	79.822	24.018	245.000	2.831	0.004*
control	11.928	0.116	43.797	12.788			

Table 1 Demographics of PWS and control cohort